Skip to main content
. Author manuscript; available in PMC: 2023 May 31.
Published in final edited form as: Mol Psychiatry. 2022 Sep 20;27(11):4642–4652. doi: 10.1038/s41380-022-01736-y

Fig. 4. Difference-in-difference estimates and 95% confidence intervals of self-reported changes in Alcohol Use Disorders Identification Test-Consumption-C (AUDIT-C) scores associated with spironolactone exposure, overall, by baseline AUDIT-C score, and by average daily dose of spironolactone.

Fig. 4

Difference-in-differences = reported AUDIT-C decrease among spironolactone-exposed individuals minus reported AUDIT-C decrease among propensity score-matched unexposed controls during the study period. *p < 0.05, ****p < 0.0001, NS not significant.